Abstract:Background Early-stage and metastatic breast cancer (MBC) exhibit genomic heterogeneity, with inter-patient variability between primary tumors, intra-patient variability of primary tumors versus metastasis, and even between different metastatic sites within the same patient. Response to therapy in MBC can also be heterogeneous, termed "mixed response", with different degrees of responsiveness to the same drug(s) across metastatic sites within the same patient. Whether this treatment response variability is influenced by factors such as intrinsic characteristics of metastatic lesions and/or the microenvironment is unknown. Through genomic analysis, we aim to identify genomic features that may explain mixed clinical responses across metastatic sites, which will also provide valuable insights into treatment sensitivity and resistance. Methods Eligible patients with MBC were identified from the UNC Rapid Autopsy Program (RAP) with primary tumors and multiple metastases (≥ 2 different sites) with RNA sequencing data. An independent radiologist retrospectively reviewed imaging studies to identify patients with mixed radiographic responses to a defined line of therapy. The response to treatment was categorized for each metastasis, defined as a complete or partial response, as stabilization ≥ 6 months. Tumor measurements were performed for each patient at different time points. We performed supervised learning with linear regression incorporating "RNA sequencing-based gene expression signatures" as a fixed effect and "patient" as a random effect. We performed two different analyses: (1) Using all tumors and (2) using Basal-like tumors only. We finally selected significant signatures with a p-value >0.05. Results Ten patients with mixed response were identified, and 33 metastases were used for the analysis; 3 had de novo stage IV disease, 5 had triple-negative (TNBC), 4 HER2+, and 4 hormone receptor+ (HR+/HER2-) disease. Of 33 metastases, 6 were brain, 8 liver, 7 lung, and 12 "other". Regarding intrinsic subtype, 15 metastatic tumors were Basal-like, 3 HER2-Enriched (HER2E), 6 Luminal A, and 9 Luminal B. In this dataset, 6 metastatic lesions showed response and 27 non-response. When analyzing all 33 metastases, KRAS high expression, KRAS amplicon, 16q23 amplicon, and apocrine features correlated with response independently of metastatic site. Higher T reg and CDKN2A gene expression levels were associated with non-response in metastasis. Within Basal-like subtype metastases only (N=15), CD8 T cells, PI3K pathway, KRAS gene and amplicon, 16q23 amplicon, and Basal-like-associated 5q11 loss correlated with response. However, T reg cells, higher levels of CDKN2A gene, and stem-cell-like features were associated with treatment non-response. Conclusions By examining matched metastases with discordant responsiveness to treatment within individual patients, this genomic analysis provides valuable insight into treatment sensitivity and resistance. Higher T reg cells and CDKN2A gene expression values correlate with non-response, while the KRAS gene, KRAS amplicon, and the 16q23 amplicon were associated with response. These results suggest that the molecular tumor and microenvironment features of metastases may contribute to sensitivity and resistance to therapy in MBC. Further validation and exploration are needed in larger multi-metastatic cohorts to fully understand the clinical implications of these findings. Citation Format: Susana Garcia-Recio, Paola Zagami, Amy Wheless, Kerry Thomas, Lisa Carey, Charles M Perou. Understanding metastasis mixed-treatment responses through genomic analyses [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl) nr PO4-06-04.

Unstable Genome and Transcriptome Dynamics during Tumor Metastasis Contribute to Therapeutic Heterogeneity in Colorectal Cancers

Differential Response to EGFR- and VEGF-targeted Therapies in Patient-Derived Tumor Tissue Xenograft Models of Colon Carcinoma and Related Metastases

Abstract PO4-06-04: Understanding metastasis mixed-treatment responses through genomic analyses

Transcriptome analysis of heterogeneity in mouse model of metastatic breast cancer

Copy number and transcriptome alterations associated with metastatic lesion response to treatment in colorectal cancer

Co-Evolution of Somatic Variation in Primary and Metastatic Colorectal Cancer May Expand Biopsy Indications in the Molecular Era

Whole Genome Sequencing Puts Forward Hypotheses on Metastasis Evolution and Therapy in Colorectal Cancer

Metabolic Heterogeneity of Tumor Cells and its Impact on Colon Cancer Metastasis: Insights from Single-Cell and Bulk Transcriptome Analyses

Multiregion whole-exome sequencing of matched primary and metastatic tumors revealed genomic heterogeneity and suggested polyclonal seeding in colorectal cancer metastasis

Abstract 4360: Integrative analysis of multiplex interphase FISH copy number with whole exome sequencing identifies tumor evolution in Stage II colon cancer

Abstract 7353: Exploring intrapatient heterogeneity in metastatic breast cancer: Insights into tumor evolution from a warm procurement trial

Abstract IA015: Combined single cell atlasing and organoid modeling reveal progressive plasticity during human colorectal cancer metastasis

Single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer tumors

Next Generation Sequencing Reveals the Phylogenetic Relationship of Multi-Organ Metastatic Colon Cancer and Molecular Determinants of Metastasis.

Dissecting the heterogeneities of the tumor microenvironment between metastatic and nonmetastatic primary colorectal cancer patients by single-cell RNA sequencing

Abstract P3-06-01: Clonal Evolution and Heterogeneity in Breast Tumors Treated with Neoadjuvant HER2-targeted Therapy

Single-cell Analysis Reveals Inter- and Intratumour Heterogeneity in Metastatic Breast Cancer

A Cohort Study on the Molecular Mechanism of Distinct Therapeutic Effects and Prognosis in Chinese Colorectal Cancer Patients Who Underwent Neoadjuvant or Surgical Therapies.

Single-cell transcriptome analysis reveals subtype-specific clonal evolution and microenvironmental changes in liver metastasis of pancreatic adenocarcinoma and their clinical implications

Multiplexed mosaic tumor models reveal natural phenotypic variations in drug response within and between populations

Heterogenous Profiles Between Matched Primary Tumors and Brain Metastases Reveal Tumor Evolution